KyleLennon
Member
- Messages
- 54
- Likes
- 3
Sarepta has been pursuing strategic collaborations for the development of its disease- modifying DMD pipeline ever since it gained approval for Exondys 51.
Its quarterly revenue growth was 956.60%, super awesome!!
If you look at its performance, its stock price is higher and higher.
Do you think it will continue to rise, will you invest it?
Its quarterly revenue growth was 956.60%, super awesome!!
If you look at its performance, its stock price is higher and higher.
Do you think it will continue to rise, will you invest it?